Dec 16, 2024 06:44AM H.C. Wainwright Downgrades Carisma Therapeutics Inc (CARM) to Neutral

Dec 12, 2024 01:49AM Baird Downgrades Carisma Therapeutics Inc (CARM) to Neutral

Dec 11, 2024 09:02AM Evercore ISI Downgrades Carisma Therapeutics Inc (CARM) to In Line

Dec 9, 2024 04:10PM BTIG Downgrades Carisma Therapeutics Inc (CARM) to Neutral

Dec 9, 2024 08:34AM Carisma Therapeutics (CARM) plans reduction in the workforce by 34%

Nov 25, 2024 06:39AM Carisma Therapeutics Inc (CARM) PT Lowered to $5 at H.C. Wainwright

Nov 11, 2024 07:13AM D. Boral Capital Reiterates Buy Rating on Carisma Therapeutics Inc (CARM)

Nov 8, 2024 07:30AM Carisma Therapeutics (CARM) Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma

Oct 30, 2024 04:31PM Carisma Therapeutics (CARM) Appoints Sohanya Cheng to its Board

Oct 30, 2024 07:16AM EF Hutton Starts Carisma Therapeutics Inc (CARM) at Buy

Sep 10, 2024 07:31AM Carisma Therapeutics (CARM) and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases

Aug 8, 2024 08:58AM Carisma Therapeutics (CARM) Misses Q2 EPS by 27c

Aug 6, 2024 07:30AM Carisma Therapeutics (CARM) Appoints Scott Friedman and Ira Tabas to Scientific Advisory Board

Jul 1, 2024 07:31AM Carisma Therapeutics (CARM) Appoints Marella Thorell and David Scadden to its Board

Jun 27, 2024 06:39AM H.C. Wainwright Reiterates Buy Rating on Carisma Therapeutics Inc (CARM)

Jun 25, 2024 07:30AM Carisma Therapeutics (CARM) Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors